Work

Effectiveness of Methylprednisolone against COVID-19–related Guillain–Barré Syndrome: A Single Case Report

Year: 2024

Type: article

Abstract: The first-line treatment for GBS is plasma exchange or intravenous immunoglobulin. In contrast, corticosteroids are not recommended for treating GBS. However, COVID-19–related Guillain–Barré syndrome occurs via mechanisms different from other infectious diseases. A 63-year-old woman experienced back pain following COVID-19, progressing to numbness/weakness of the extremities, left peripheral facial nerve palsy, and abnormal sensation/allodynia in the face and extremities. Compound muscle action potentials showed severe temporal dispersion. Intravenous immunoglobulin administration slightly improved the lower limb muscle weakness and facial nerve palsy but was ineffective for the pain in the chest and back and numbness of the extremities. Three courses of intravenous methylprednisolone (IVMP) enabled the patient to walk unassisted. This case is the first to demonstrate IVMP's effectiveness against COVID-19–related Guillain–Barré syndrome. Further studies are required to establish treatments for COVID-19–related Guillain–Barré syndrome.

Source: Neuroimmunology Reports

DOI: 10.1016/j.nerep.2024.100212

Authors: Azusa Sunouchi, Ryota Amano, Ayumi Uchibori

Institutions: Fujiyoshida Municipal Medical Center, Kyorin University

Language: English

Topic: Peripheral Neuropathies and Disorders

Subfield: Clinical Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,000